

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Xuanzhu Biopharmaceutical Co., Ltd.

軒竹生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2575)

**POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING
AND
ABOLISHMENT OF THE SUPERVISORY COMMITTEE AND
AMENDMENTS TO
THE ARTICLES OF ASSOCIATION**

References are made to (i) the circular (the “**Circular**”) and (ii) the notice (the “**Notice**”) both dated May 27, 2026 issued by Xuanzhu Biopharmaceutical Co., Ltd. (the “**Company**”) in relation to the 2025 annual general meeting of the Company (the “**AGM**”) held at 10:30 a.m. on Thursday, June 18, 2026 at Jing Tai Lan Meeting Room, Wanda Vista Beijing.

The Board is pleased to announce that the results of voting were taken by way of poll at the AGM pursuant to Rule 13.39(4) of the Listing Rules and all proposed resolutions set out in the Circular were duly passed. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Circular.

ATTENDANCE OF THE MEETING

As of the time of the AGM, the Company had a total of 517,947,790 Shares in issue, which was the total number of Shares entitling the Shareholders to attend and vote for or against the resolutions proposed at the AGM. Among these, none of the Shares was held as treasury Shares (including any treasury Shares held or deposited with the Central Clearing and Settlement System operated by Hong Kong Securities Clearing Company Limited), and no voting rights attached to the treasury Shares may be exercised at the AGM. There were no Shares entitling the Shareholders to attend and abstain from voting in favour of any resolutions proposed for consideration and approval by the Shareholders at the AGM as set out in Rule 13.40 of the Listing Rules. The total number of Shares entitling the holders to attend and vote for or against all the resolutions in the Notice proposed at the AGM was 428,607,457. There were no repurchased Shares which are pending cancellation and accordingly should be excluded from the total number of issued Shares for the purposes of the AGM. All Directors attended the AGM in person or by electronic means.

To the best of the Directors' knowledge, information and belief, Ms. Xu Yanjun, Dr. Li Jia Kui and Dr. Shih Cheng-Kon, all being executive Directors, holding 13,180,910, 3,020,800 and 1,700,000 Shares respectively, are required to abstain from voting on the resolution number 7 proposed by the Company at the AGM to consider and approve the directors' remuneration (allowance) plan pursuant to the applicable laws of the PRC. To the best of the Directors' knowledge, information and belief, save as disclosed herein, no Shareholders were required under the Listing Rules to abstain from voting at the AGM and no parties have stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions proposed at the AGM.

All the resolutions as set out in the Notice were put to vote by way of poll by the Shareholders (including their proxies and authorised representatives) at the AGM.

POLL RESULTS OF THE AGM

The poll results of the proposed resolutions (the “**Resolutions**”) at the AGM were as follows:

ORDINARY RESOLUTIONS ⁽¹⁾		Number of votes (%)		
		For	Against	Abstain
1.	To consider and approve the 2025 Report of the Board.	427,969,298 (99.851109%)	576,159 (0.134426%)	62,000 (0.014465%)
2.	To consider and approve the 2025 Report of the Supervisory Committee.	427,969,298 (99.851109%)	576,159 (0.134426%)	62,000 (0.014465%)
3.	To consider and approve the 2025 Audited Consolidated Financial Statements.	427,969,298 (99.851109%)	576,159 (0.134426%)	62,000 (0.014465%)
4.	To consider and approve the 2025 Annual Report.	427,969,298 (99.851109%)	576,159 (0.134426%)	62,000 (0.014465%)
5.	To consider and approve the profit distribution plan for the year ended December 31, 2025.	427,969,298 (99.851109%)	576,159 (0.134426%)	62,000 (0.014465%)
6.	To consider and approve the 2025 work report of independent non-executive Directors.	427,969,298 (99.851109%)	576,159 (0.134426%)	62,000 (0.014465%)
7.	To consider and approve the Directors' remuneration (allowance) plan.	418,534,098 (98.737266%)	576,159 (0.135923%)	4,776,400 (1.126811%)
8.	To consider and approve the re-appointment of the auditor for the year of 2026.	427,393,139 (99.716683%)	0 (0.000000%)	1,214,318 (0.283317%)

SPECIAL RESOLUTIONS ⁽¹⁾		Number of votes (%)		
		For	Against	Abstain
9.	To consider and approve the proposed grant of general mandate to the Board to repurchase H Shares.	427,969,298 (99.851109%)	576,159 (0.134426%)	62,000 (0.14465%)
10.	To consider and approve the proposed grant of general mandate to the Board to issue H Shares.	427,968,798 (99.850992%)	576,659 (0.134543%)	62,000 (0.14465%)
11.	To consider and approve the proposed abolishment of the Supervisory Committee and the amendments to the Articles of Association.	427,969,298 (99.851109%)	576,159 (0.134426%)	62,000 (0.14465%)

Note:

(1) Please refer to the Circular for the full text of the Resolutions.

As more than one-half of the votes were cast in favour of ordinary resolutions number 1 to 7, and two-thirds of the votes were cast in favour of special resolutions number 9 to 11, all resolutions proposed at the AGM were duly passed by way of poll by the Shareholders.

VOTE TAKING

Computershare Hong Kong Investor Services Limited, the H Share registrar of the Company, acted as the H Share scrutineer at the AGM for the purpose of vote-taking. Two Shareholder representatives were also appointed as the vote counters and scrutineers for the AGM.

ABOLISHMENT OF THE SUPERVISORY COMMITTEE AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION

Reference is also made to the Company's announcement dated May 26, 2026 and the Circular, in relation to, among others, the proposed amendments to the Articles of Association and the abolishment of the Supervisory Committee.

A special resolution was passed by the Shareholders at the AGM to approve the abolishment of the Supervisory Committee and amendments to the Articles of Association. Accordingly, effective from June 18, 2026, the Company will no longer have the Supervisory Committee, and the current members of the Supervisory Committee shall cease to hold office as Supervisors, and the amended Articles of Association shall become effective from the date of the AGM. The full text of the amended Articles of Association will be published on the websites of the Company (www.xuanzhubio.com) and the Stock Exchange (www.hkexnews.hk). Shareholders should be aware that the English version of the Articles

of Association is a translation from the Chinese version. The Chinese version of the Articles of Association shall prevail in the case of discrepancies or inconsistencies between the two versions.

The Supervisors have confirmed that they have no disagreement with the Company or the Board, and there are no other matters that need to be brought to the attention of the Stock Exchange and Shareholders.

The Company would like to express heartfelt gratitude to all the Supervisors for their contributions to the Company during their tenures.

By order of the Board
Xuanzhu Biopharmaceutical Co., Ltd.
Ms. Xu Yanjun
Chairperson of the Board and executive Director

Hong Kong, June 18, 2026

As of the date of this announcement, the Board comprises (i) Ms. Xu Yanjun and Dr. Shih Cheng-Kon as executive Directors; (ii) Ms. Li Huiying, Mr. Yu Lifeng and Ms. Chen Yanling as non-executive Directors; (iii) Ms. Yue Xin as employee representative Director and (iv) Mr. Liu Shuo, Ms. Wang Yu and Mr. Fan Chi Chiu as independent non-executive Directors.